<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Mixed connective tissue disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Mixed connective tissue disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Mixed connective tissue disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Voon Ong, PhD, FRCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John S Axford, DSc, MD, FRCP, FRCPCH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Siobhan M Case, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mixed connective tissue disease (MCTD) is a systemic rheumatic disease characterized by the presence of high-titer anti-U1 ribonucleoprotein (RNP) antibodies in combination with clinical features commonly seen in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), and polymyositis (PM).
        </p>
        <p>
         It often takes several years before enough overlapping features have appeared to be confident that MCTD is the most appropriate diagnosis. The distinctive overlap features of SLE, SSc, inflammatory arthritis, and PM commonly appear sequentially over time. Thus, in its early stages, MCTD may present with features of undifferentiated connective tissue disease (UCTD).
        </p>
        <p>
         This topic will review the clinical manifestations, diagnosis, treatment and prognosis of MCTD. UCTD is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1831.html" rel="external">
          "Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H32850538">
         <span class="h1">
          EPIDEMIOLOGY AND PATHOGENESIS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – There is limited information regarding the prevalence and incidence of mixed connective tissue disease (MCTD) [
         <a href="#rid1">
          1-5
         </a>
         ]. MCTD occurs worldwide and affects all races, with a peak incidence in adolescence and the 20s [
         <a href="#rid6">
          6-8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Estimates of the annual incidence of MCTD range from 0.2 to 1.9 per 100,000 adults [
         <a href="#rid1">
          1,2
         </a>
         ]. MCTD is much more common in females than males, although estimates of the difference range widely (from 3:1 to 16:1) [
         <a href="#rid1">
          1,9-11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – Little is known about the etiology of MCTD.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Exposures
         </strong>
         – Drug-induced MCTD is a rare occurrence but has been associated with anti-tumor necrosis factor (TNF) therapy [
         <a href="#rid12">
          12,13
         </a>
         ]. Vinyl chloride [
         <a href="#rid14">
          14
         </a>
         ] and silica [
         <a href="#rid15">
          15,16
         </a>
         ] are the only environmental agents that have been associated with MCTD. Coronavirus disease 2019 (COVID-19) infections have been associated with disease flares, including diffuse lymphadenopathy and lupus nephritis [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Genetics
         </strong>
         – Although there is limited evidence for potential environmental factors for MCTD,
         <em>
          HLA-DRB1*04:01
         </em>
         has been linked with MCTD [
         <a href="#rid19">
          19
         </a>
         ]. Although not specific, MCTD has been associated with variations of DNA methylation of genes in the type I interferon pathway [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Target epitope
         </strong>
         – Anti-U1 ribonucleoprotein (RNP) antibodies associated with MCTD target a different epitope than anti-U1 RNP antibodies associated with systemic lupus erythematosus (SLE). This implies that anti-U1 RNP antibodies may play different roles in the pathogenesis of MCTD versus SLE [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Epitope spreading has been proposed as a potential mechanism to account for the change in clinical disease expression [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Controversy regarding diagnosis
         </strong>
         – Since the disease was first defined in 1972, there has been disagreement among experts as to whether MCTD should be considered a distinct clinical entity or whether it might represent an early stage of another well-defined systemic rheumatic disease (eg, SLE or systemic sclerosis [SSc]) [
         <a href="#rid23">
          23-27
         </a>
         ]. Four different diagnostic criteria have been proposed, reflecting the ongoing controversy over its definition [
         <a href="#rid28">
          28-31
         </a>
         ]. (See
         <a class="local">
          'Establishing the diagnosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The following observations support the concept of MCTD as a distinct clinical diagnosis:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Raynaud phenomenon
         </strong>
         – Patients with MCTD nearly always have an early development of Raynaud phenomenon [
         <a href="#rid23">
          23,25,32
         </a>
         ] and a nailfold capillary pattern that is the same as in SSc but different from classical SLE [
         <a href="#rid33">
          33
         </a>
         ]. Raynaud phenomenon only occurs in approximately 25 percent of patients with SLE. (See
         <a class="local">
          'Raynaud phenomenon'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pulmonary arterial hypertension
         </strong>
         – Patients with MCTD are more likely to develop pulmonary arterial hypertension (PAH) than patients with SLE or SSc. (See
         <a class="local">
          'Pulmonary arterial hypertension'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Autoantibodies
         </strong>
         – Patients with MCTD are more likely than SLE patients to test positively for rheumatoid factor [
         <a href="#rid34">
          34,35
         </a>
         ] or anti-citrullinated peptide antibodies (ACPA) [
         <a href="#rid36">
          36
         </a>
         ]. MCTD patients with RF or ACPA are more likely to develop an erosive arthritis [
         <a href="#rid34">
          34,35,37,38
         </a>
         ]. (See
         <a class="local">
          'Arthritis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Similarly, these patients are more likely to have more than one autoantibody including anti-Sm and double-stranded deoxyribonucleic acid (dsDNA) compared with those with SSc [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The early clinical features of mixed connective tissue disease (MCTD) may include puffy fingers, fatigue, arthralgias, myalgias, low-grade fever, and Raynaud phenomenon [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3174595500">
         <span class="h2">
          Lupus-like features
         </span>
        </p>
        <p class="headingAnchor" id="H3453118760">
         <span class="h3">
          Cutaneous
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin involvement occurs in most patients with MCTD and is often a presenting feature [
         <a href="#rid42">
          42
         </a>
         ]. MCTD may share many of the cutaneous features of systemic lupus erythematosus (SLE), including chilblains (pernio), discoid plaques, malar rash, panniculitis, and mucosal ulcerations.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chilblains
         </strong>
         – Chilblains presents as erythematous to violaceous macules, papules, plaques, or nodules in sites of cold exposure, generally in the fingers and toes. Chilblain lesions, if present, can be associated with sausage-like fingers leading to digital ulcers and infarcts, resulting in ice-pick scars, digital atrophy, and poor nail growth  (
         <a class="graphic graphic_picture graphicRef94183" href="/z/d/graphic/94183.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef94184" href="/z/d/graphic/94184.html" rel="external">
          picture 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/13758.html" rel="external">
          "Pernio (chilblains)", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Discoid plaques
         </strong>
         – Discoid plaques present as discrete, erythematous, indurated plaques covered by scale  (
         <a class="graphic graphic_picture graphicRef107705" href="/z/d/graphic/107705.html" rel="external">
          picture 3
         </a>
         and
         <a class="graphic graphic_picture graphicRef109889" href="/z/d/graphic/109889.html" rel="external">
          picture 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">
          "Overview of cutaneous lupus erythematosus", section on 'Discoid lupus erythematosus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Malar rash
         </strong>
         – Malar rash is a form of acute cutaneous lupus erythematosus that presents as an erythematous rash across the cheeks and nose and is sometimes called a “butterfly rash”  (
         <a class="graphic graphic_picture graphicRef97045" href="/z/d/graphic/97045.html" rel="external">
          picture 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">
          "Overview of cutaneous lupus erythematosus", section on 'Acute cutaneous lupus erythematosus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Panniculitis
         </strong>
         – Panniculitis over the abdomen, legs, and breasts has been described  (
         <a class="graphic graphic_picture graphicRef85712" href="/z/d/graphic/85712.html" rel="external">
          picture 6
         </a>
         and
         <a class="graphic graphic_picture graphicRef83791" href="/z/d/graphic/83791.html" rel="external">
          picture 7
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">
          "Overview of cutaneous lupus erythematosus", section on 'Lupus profundus (lupus panniculitis)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mucus membrane involvement
         </strong>
         – Mucus membrane involvement can include orogenital and buccal ulcerations [
         <a href="#rid43">
          43-45
         </a>
         ]. All of these skin manifestations are indistinguishable from SLE  (
         <a class="graphic graphic_picture graphicRef73386 graphicRef62041 graphicRef80459" href="/z/d/graphic/73386.html" rel="external">
          picture 8A-C
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">
          "Overview of cutaneous lupus erythematosus", section on 'Mucosal manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The management of chilblains is discussed elsewhere. The other disease manifestations mentioned above are managed using the same approach used for subacute cutaneous lupus erythematosus:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13758.html" rel="external">
          "Pernio (chilblains)", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13772.html" rel="external">
          "Initial management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus", section on 'Approach to pharmacologic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2027669040">
         <span class="h3">
          Cardiac
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 30 percent of MCTD patients have symptomatic heart disease, and up to 40 percent have subclinical disease [
         <a href="#rid46">
          46
         </a>
         ]. Cardiac involvement accounts for approximately 20 percent of MCTD mortality [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         MCTD may share many of the cardiac features of SLE:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pericarditis
         </strong>
         – Pericarditis is the most common clinical manifestation of cardiac involvement, being reported in up to 40 percent of patients [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pericarditis typically presents with pleuritic substernal chest pain, which may be accompanied by an audible rub on auscultation. It may be accompanied by evidence of serositis at other sites (eg, pleural effusion). (See
         <a class="medical medical_review" href="/z/d/html/4680.html" rel="external">
          "Non-coronary cardiac manifestations of systemic lupus erythematosus in adults", section on 'Pericardial disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As with acute idiopathic pericarditis, some patients may respond to nonsteroidal antiinflammatory drugs (NSAIDs)  (
         <a class="graphic graphic_table graphicRef70067" href="/z/d/graphic/70067.html" rel="external">
          table 1
         </a>
         ) and/or a moderate-dose glucocorticoid taper  (
         <a class="graphic graphic_table graphicRef56484" href="/z/d/graphic/56484.html" rel="external">
          table 2
         </a>
         ) However, for patients with MCTD, we generally add
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         . We reserve
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         for patients with recurrent pericarditis despite hydroxychloroquine.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The management of acute pericarditis is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">
          "Acute pericarditis: Treatment and prognosis", section on 'Medical therapies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myocarditis
         </strong>
         – Myocarditis is an uncommon manifestation of MCTD [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Myocarditis may present with tachycardia, electrocardiographic abnormalities (eg, diffuse ST and T wave abnormalities), cardiomegaly, or heart failure. Myocarditis may also present as an asymptomatic troponin/creatinine kinase elevation in a patient with other signs of systemic inflammation (eg, pericarditis, arthritis). Echocardiography may demonstrate systolic and/or diastolic dysfunction. (See
         <a class="medical medical_review" href="/z/d/html/4680.html" rel="external">
          "Non-coronary cardiac manifestations of systemic lupus erythematosus in adults", section on 'Myocarditis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Myocarditis is managed using the same strategies developed for lupus myocarditis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The management myocarditis is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4680.html" rel="external">
          "Non-coronary cardiac manifestations of systemic lupus erythematosus in adults", section on 'Treatment of myocarditis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Accelerated atherosclerosis
         </strong>
         – There is also increasing recognition of accelerated atherosclerosis in both SLE and MCTD [
         <a href="#rid47">
          47,49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Atherosclerosis in MCTD may present with symptoms typical of ischemic heart disease (eg, exertional chest pain) or with nonspecific symptoms (eg, dyspnea, diaphoresis).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with SLE, risk factors for accelerated atherosclerosis include elevated high-sensitivity C-reactive protein (CRP) levels, dyslipidemia, antiendothelial antibodies, antiphospholipid antibodies, and vitamin D deficiency. (See
         <a class="medical medical_review" href="/z/d/html/4683.html" rel="external">
          "Coronary artery disease in systemic lupus erythematosus", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The management of the accelerated atherosclerosis associated with SLE is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4683.html" rel="external">
          "Coronary artery disease in systemic lupus erythematosus", section on 'Prevention and treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Conduction abnormalities
         </strong>
         – An abnormal electrocardiogram is noted in approximately 20 percent of patients. The most common electrocardiogram abnormalities include hemiblock, bundle branch block, and atrioventricular block [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         SLE-associated conduction abnormalities are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4680.html" rel="external">
          "Non-coronary cardiac manifestations of systemic lupus erythematosus in adults", section on 'Conduction abnormalities'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H75947815">
         <span class="h3">
          Renal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some degree of kidney involvement occurs in approximately 25 percent of patients [
         <a href="#rid43">
          43,50,51
         </a>
         ]. Membranous nephropathy is the most common finding  (
         <a class="graphic graphic_picture graphicRef57841 graphicRef74698 graphicRef55226 graphicRef69629 graphicRef62937" href="/z/d/graphic/57841.html" rel="external">
          picture 9A-E
         </a>
         ) [
         <a href="#rid43">
          43,50,52
         </a>
         ], and nephrotic range proteinuria may occur [
         <a href="#rid37">
          37
         </a>
         ]. Tubulointerstitial nephritis and mesangioproliferative glomerulonephritis has also been reported [
         <a href="#rid53">
          53-55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">
          "Lupus nephritis: Diagnosis and classification", section on 'Histopathologic classification of LN'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">
          "Lupus nephritis: Diagnosis and classification", section on 'Tubulointerstitial lesions'
         </a>
         .)
        </p>
        <p>
         Early kidney disease is generally asymptomatic. Proteinuria and/or hematuria may be the first sign of kidney disease, occurring prior to an increase in the serum creatinine. (See
         <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">
          "Lupus nephritis: Diagnosis and classification", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         The absence of severe kidney disease is a hallmark of MCTD [
         <a href="#rid23">
          23,47,56
         </a>
         ]. High titers of anti-U1 ribonucleoprotein (RNP) antibodies may protect against the development of diffuse proliferative glomerulonephritis, independent of whether these antibodies occur in MCTD or in SLE [
         <a href="#rid37">
          37,50
         </a>
         ]. However, the presence of hematuria or proteinuria is associated with a poor kidney prognosis and an increased risk of progression to SLE [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         The treatment of both lupus-associated membranous nephropathy and lupus nephritis are discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3093.html" rel="external">
          "Lupus nephritis: Therapy of lupus membranous nephropathy", section on 'Initial therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">
          "Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Approach to treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4001981857">
         <span class="h3">
          Neurologic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 25 percent of patients have some mild form of central nervous system (CNS) disease [
         <a href="#rid10">
          10,58
         </a>
         ]. Compared with patients with SLE, the cognitive impairment associated with MCTD is mild [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         Patients with MCTD do not develop severe neurologic complications such as cerebritis, psychosis, or seizures [
         <a href="#rid23">
          23,58
         </a>
         ]. The neurologic manifestations of MCTD include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trigeminal neuralgia
         </strong>
         – The most frequent CNS manifestation is a trigeminal (fifth cranial) nerve neuralgia, which may be the presenting feature of the disease [
         <a href="#rid60">
          60,61
         </a>
         ]. Trigeminal neuralgia is also the most common CNS problem in patients with SSc. (See
         <a class="medical medical_review" href="/z/d/html/5283.html" rel="external">
          "Trigeminal neuralgia", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Headaches
         </strong>
         – Headaches are common. They are most often vascular in origin [
         <a href="#rid62">
          62
         </a>
         ] but can be caused by aseptic meningitis [
         <a href="#rid63">
          63,64
         </a>
         ], due to the disease itself or to a reaction to NSAIDs [
         <a href="#rid65">
          65-67
         </a>
         ], and by muscle tension and myofascial trigger points. (See
         <a class="medical medical_review" href="/z/d/html/3349.html" rel="external">
          "Evaluation of headache in adults", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sensorineural hearing loss
         </strong>
         – Sensorineural hearing loss is often not recognized, but it is reported to occur in approximately 50 percent of MCTD patients [
         <a href="#rid68">
          68
         </a>
         ]. There is no association between sensorineural hearing loss and age or disease duration. (See
         <a class="medical medical_review" href="/z/d/html/6847.html" rel="external">
          "Sudden sensorineural hearing loss in adults: Evaluation and management", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other neurologic manifestations
         </strong>
         – Isolated cases of cerebral hemorrhage [
         <a href="#rid69">
          69
         </a>
         ], transverse myelitis [
         <a href="#rid70">
          70
         </a>
         ], cauda equina syndrome [
         <a href="#rid71">
          71
         </a>
         ], retinal vasculitis [
         <a href="#rid72">
          72
         </a>
         ], progressive multifocal encephalopathy [
         <a href="#rid73">
          73,74
         </a>
         ], demyelinating neuropathy [
         <a href="#rid75">
          75,76
         </a>
         ], reversible posterior encephalopathy [
         <a href="#rid77">
          77
         </a>
         ], and adhesive arachnoiditis [
         <a href="#rid78">
          78
         </a>
         ] have also been reported. (See
         <a class="medical medical_review" href="/z/d/html/4863.html" rel="external">
          "Neurologic and neuropsychiatric manifestations of systemic lupus erythematosus", section on 'Clinical syndromes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The management of trigeminal neuralgia, headache, autoimmune sensorineural hearing loss, and other features of neuropsychiatric lupus are discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5283.html" rel="external">
          "Trigeminal neuralgia", section on 'First-line therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4863.html" rel="external">
          "Neurologic and neuropsychiatric manifestations of systemic lupus erythematosus", section on 'Headache'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6847.html" rel="external">
          "Sudden sensorineural hearing loss in adults: Evaluation and management", section on 'Treatment: Glucocorticoid therapy for all patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4863.html" rel="external">
          "Neurologic and neuropsychiatric manifestations of systemic lupus erythematosus", section on 'Clinical syndromes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4665.html" rel="external">
          "Manifestations of systemic lupus erythematosus affecting the peripheral nervous system", section on 'Peripheral neuropathies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H785862820">
         <span class="h3">
          Hematologic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoimmune thrombocytopenia and autoimmune hemolytic anemia are uncommon manifestations of MCTD. When these manifestations occur, they are managed using the same strategies developed for the hematologic manifestations of SLE.
        </p>
        <p>
         Early thrombocytopenia and anemia are generally asymptomatic and are often detected through routine laboratory testing. There are multiple causes of thrombocytopenia and anemia, many of which are not immune mediated. (See
         <a class="medical medical_review" href="/z/d/html/4670.html" rel="external">
          "Hematologic manifestations of systemic lupus erythematosus", section on 'Causes of anemia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4670.html" rel="external">
          "Hematologic manifestations of systemic lupus erythematosus", section on 'Thrombocytopenia'
         </a>
         .)
        </p>
        <p>
         The management of SLE-associated thrombocytopenia and autoimmune hemolytic anemia are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7078.html" rel="external">
          "Warm autoimmune hemolytic anemia (AIHA) in adults", section on 'Initial management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">
          "Initial treatment of immune thrombocytopenia (ITP) in adults", section on 'Overview of decision-making'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1008101662">
         <span class="h3">
          Pulmonary
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with MCTD may rarely develop a wide spectrum of pulmonary complications associated with SLE, including pleural effusions, pleuritic pain, alveolar hemorrhage, and thromboembolic disease [
         <a href="#rid79">
          79
         </a>
         ]. (See
         <a class="local">
          'Interstitial lung disease'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pleural effusions
         </strong>
         – Plural effusions are often bilateral and may be associated with a cough, dyspnea, or fever. Pleuritic chest pain may occur in the absence of a pleural effusion and may be associated with a pleural rub on examination. (See
         <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">
          "Pulmonary manifestations of systemic lupus erythematosus in adults", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alveolar hemorrhage
         </strong>
         – Alveolar hemorrhage may be associated with hemoptysis, dyspnea, or anemia, developing over a few days. (See
         <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">
          "Pulmonary manifestations of systemic lupus erythematosus in adults", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thromboembolic disease
         </strong>
         – Thromboembolic disease may present as a pulmonary embolism (with cough, dyspnea, and pleuritic chest pain) or a deep venous thrombosis (with unilateral lower extremity edema). (See
         <a class="medical medical_review" href="/z/d/html/8253.html" rel="external">
          "Epidemiology and pathogenesis of acute pulmonary embolism in adults", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The management of the pulmonary manifestations of SLE is discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">
          "Pulmonary manifestations of systemic lupus erythematosus in adults", section on 'Pleural disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">
          "Pulmonary manifestations of systemic lupus erythematosus in adults", section on 'Pulmonary hemorrhage'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Definitive therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H418367702">
         <span class="h2">
          Scleroderma-like features
         </span>
        </p>
        <p class="headingAnchor" id="H1341577397">
         <span class="h3">
          Raynaud phenomenon
         </span>
         <span class="headingEndMark">
          —
         </span>
         Raynaud phenomenon is an early feature of MCTD in most patients [
         <a href="#rid80">
          80
         </a>
         ]. The absence of Raynaud phenomenon should cast doubt on a diagnosis of MCTD.
        </p>
        <p>
         In Raynaud phenomenon, vasospasm leads to a sharply demarcated color change of the digits (initially white, due to constricted blood flow, then blue, due to cyanosis). Rarely, patients with Raynaud phenomenon may also develop digital ischemia. (See
         <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">
          "Clinical manifestations and diagnosis of Raynaud phenomenon", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         As with systemic sclerosis (SSc), abnormal nailfold capillaroscopy with giant capillaries, abnormal shapes, and low capillary density is a common feature of MCTD (occurring in 38 to 70 percent of cases), and this can accrue over time [
         <a href="#rid81">
          81-83
         </a>
         ]. The capillary pattern is characterized by dilation and dropout  (
         <a class="graphic graphic_picture graphicRef50044" href="/z/d/graphic/50044.html" rel="external">
          picture 10
         </a>
         ). Nailfold capillaroscopy can be performed at the bedside and can be used to determine which patients with Raynaud phenomenon are at higher risk of developing a rheumatic disease, such as MCTD [
         <a href="#rid84">
          84
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">
          "Clinical manifestations and diagnosis of Raynaud phenomenon", section on 'Nailfold capillary microscopy'
         </a>
         .)
        </p>
        <p>
         The management of Raynaud phenomenon and scleroderma-associated digital ischemia is discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7540.html" rel="external">
          "Treatment of Raynaud phenomenon: Initial management", section on 'Initial management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7552.html" rel="external">
          "Treatment of Raynaud phenomenon: Refractory or progressive ischemia", section on 'Severe acute ischemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2417272200">
         <span class="h3">
          Gastrointestinal dysmotility
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastrointestinal involvement is a common clinical overlap feature with SSc, occurring in approximately 60 to 80 percent of patients [
         <a href="#rid85">
          85,86
         </a>
         ]. Disordered motility in the upper gastrointestinal tract is the most common problem, and this may be associated with development of SSc [
         <a href="#rid24">
          24,87,88
         </a>
         ].
        </p>
        <p>
         Dysmotility of the upper gastrointestinal tract most commonly presents with heartburn, dysphagia, or odynophagia. Advanced dysphagia may lead to regurgitation of food or fluids. (See
         <a class="medical medical_review" href="/z/d/html/7548.html" rel="external">
          "Gastrointestinal manifestations of systemic sclerosis (scleroderma)", section on 'Esophageal involvement'
         </a>
         .)
        </p>
        <p>
         Esophageal biopsies may show severe atrophy and loss of smooth muscle cells in the muscular layer of the lower esophagus, followed by fibrosis  (
         <a class="graphic graphic_diagnosticimage graphicRef97046" href="/z/d/graphic/97046.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid89">
          89
         </a>
         ]. The atrophied tissues show deposition of immunoglobulin G (IgG) and C3 on immunofluorescence microscopy.
        </p>
        <p>
         Gastrointestinal dysmotility is managed according to the treatment guidelines established for similar disorders in scleroderma [
         <a href="#rid90">
          90
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7556.html" rel="external">
          "Treatment of gastrointestinal disease in systemic sclerosis (scleroderma)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1191958195">
         <span class="h3">
          Interstitial lung disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Interstitial lung disease (ILD) occurs in approximately 50 to 66 percent of patients with MCTD [
         <a href="#rid91">
          91-94
         </a>
         ]. Six percent of patients with connective tissue disease (CTD)-ILD have MCTD [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
         Nonspecific interstitial pneumonia (NSIP) accounts for most of ILD in MCTD. The most common high-resolution computed tomography (CT) findings are septal thickening, ground-glass opacities, non-septal linear opacities, and peripheral/lower lobe predominance [
         <a href="#rid96">
          96,97
         </a>
         ], which are similar to the findings in SSc-ILD [
         <a href="#rid93">
          93,98
         </a>
         ].
        </p>
        <p>
         NSIP commonly presents with dyspnea and cough, developing over weeks to months, associated with bibasilar fine inspiratory crackles. Clubbing and right heart failure are uncommon manifestations of NSIP. (See
         <a class="medical medical_review" href="/z/d/html/4368.html" rel="external">
          "Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112195.html" rel="external">
          "Causes, clinical manifestations, evaluation, and diagnosis of nonspecific interstitial pneumonia", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         Risk factors for the development of MCTD-ILD include [
         <a href="#rid22">
          22,87,99-102
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Raynaud phenomenon
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dysphagia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated CRP
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Giant capillaries on nailfold capillaroscopy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anti-Sm or anti-Ro52 antibodies
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patulous esophagus
        </p>
        <p>
        </p>
        <p>
         Additionally, digital ulceration was reported to be a risk factor for more severe lung disease [
         <a href="#rid100">
          100,101
         </a>
         ].
        </p>
        <p>
         Untreated MCTD-ILD is usually progressive, with the development of severe pulmonary fibrosis in 25 percent of patients after four years of follow-up [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
         The assessment and management of scleroderma lung disease are discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4368.html" rel="external">
          "Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">
          "Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Initiating therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H308062367">
         <span class="h3">
          Digital vasculopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Swollen digits and occasionally total hand edema are present in 53 to 72 percent of cases at presentation and 46 to 92 percent after follow-up  (
         <a class="graphic graphic_picture graphicRef80351" href="/z/d/graphic/80351.html" rel="external">
          picture 11
         </a>
         ) [
         <a href="#rid25">
          25,43,103
         </a>
         ]. The fingers may initially appear puffy, which represents an initial edematous phase due to vascular (rather than articular) damage, followed by a fibrotic phase that leads to induration  (
         <a class="graphic graphic_figure graphicRef96749" href="/z/d/graphic/96749.html" rel="external">
          figure 1
         </a>
         ). Acrosclerosis leading to digital autoamputation have also been described  (
         <a class="graphic graphic_picture graphicRef120012" href="/z/d/graphic/120012.html" rel="external">
          picture 12
         </a>
         ) [
         <a href="#rid104">
          104
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13769.html" rel="external">
          "Evaluation of adults with cutaneous lesions of vasculitis", section on 'Suggestive findings'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">
          "Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Digital vasculopathy'
         </a>
         .)
        </p>
        <p>
         The characteristic vascular lesion of MCTD is bland intimal proliferation and medial hypertrophy affecting medium- and small-sized vessels [
         <a href="#rid105">
          105
         </a>
         ]; this is also the characteristic pathology in pulmonary arterial hypertension (PAH) and renovascular crises  (
         <a class="graphic graphic_picture graphicRef73386 graphicRef62041 graphicRef80459" href="/z/d/graphic/73386.html" rel="external">
          picture 8A-C
         </a>
         ) [
         <a href="#rid10">
          10
         </a>
         ]. Angiographic studies reveal a high prevalence of medium-sized arterial occlusions  (
         <a class="graphic graphic_diagnosticimage graphicRef58584" href="/z/d/graphic/58584.html" rel="external">
          image 2
         </a>
         ) [
         <a href="#rid33">
          33
         </a>
         ]. These pathologic changes differ from those usually noted in SLE, in which perivascular inflammatory infiltrates and necrosis are more characteristic.
        </p>
        <p>
         The management of digital ischemia is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7552.html" rel="external">
          "Treatment of Raynaud phenomenon: Refractory or progressive ischemia", section on 'Severe acute ischemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1715931862">
         <span class="h3">
          Pulmonary arterial hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         PAH is present in 13.2 percent of patients with MCTD [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
         PAH commonly presents with dyspnea, fatigue, and symptoms of right heart failure (eg, exertional chest pain, exertional syncope, abdominal pain/swelling due to hepatic congestion). (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         PAH is a major cause of death in MCTD [
         <a href="#rid10">
          10,107
         </a>
         ]. However, the prognosis of PAH-MCTD is better than the prognosis of PAH associated with SSc or SLE, despite similar histologic changes affecting the pulmonary arteries (eg, intimal hyperplasia, medial hypertrophy, plexiform lesions, and local microthrombi  (
         <a class="graphic graphic_picture graphicRef88300" href="/z/d/graphic/88300.html" rel="external">
          picture 13
         </a>
         )) [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         Risk factors of PAH-MCTD include low capillary density on nailfold capillaroscopy and antiendothelial or anticardiolipin antibodies [
         <a href="#rid109">
          109-111
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The use of immunosuppression for the management of MCTD-associated PAH is controversial [
         <a href="#rid112">
          112-115
         </a>
         ]. A systematic review indicated that 19 percent of patients with MCTD-associated PAH responded to immunosuppression [
         <a href="#rid116">
          116
         </a>
         ]. However, scleroderma-associated PAH is generally thought to be refractory to immunosuppressive therapies.
        </p>
        <p>
         The management of scleroderma-associated PAH is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8256.html" rel="external">
          "Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Treatment and prognosis", section on 'General measures'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1955899370">
         <span class="h3">
          Cutaneous sclerosis and calcinosis cutis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with MCTD rarely develop the cutaneous manifestations of scleroderma, such as cutaneous sclerosis and calcinosis cutis [
         <a href="#rid117">
          117,118
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cutaneous sclerosis
         </strong>
         – Cutaneous sclerosis presents as thickening of the skin of the extremities and the face, sparing the back  (
         <a class="graphic graphic_figure graphicRef96747" href="/z/d/graphic/96747.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">
          "Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Cutaneous manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Calcinosis cutis
         </strong>
         – Cutaneous cutis presents as hard deposits just below the surface of the skin, most commonly affecting the hands and feet  (
         <a class="graphic graphic_picture graphicRef101501" href="/z/d/graphic/101501.html" rel="external">
          picture 14
         </a>
         and
         <a class="graphic graphic_picture graphicRef101502" href="/z/d/graphic/101502.html" rel="external">
          picture 15
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/13756.html" rel="external">
          "Calcinosis cutis: Etiology and patient evaluation", section on 'Autoimmune connective tissue disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         When these disease manifestations occur, they are managed using the same strategies used for scleroderma.
        </p>
        <p>
         The management of scleroderma-associated sclerosis and calcinosis cutis are discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">
          "Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults", section on 'Skin involvement'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/100751.html" rel="external">
          "Calcinosis cutis: Management", section on 'Treatment of calcinosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2131663722">
         <span class="h3">
          Scleroderma renal crisis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Scleroderma renal crisis (SRC) is an uncommon manifestation of MCTD. The diagnosis of SRC should be considered in any patient with MCTD presenting with new or worsening hypertension.
        </p>
        <p>
         SRC is characterized by acute kidney injury with abrupt onset (or worsening) of hypertension. It is accompanied by a thrombotic microangiopathy, which is associated with thrombocytopenia, anemia, and schistocytes.
        </p>
        <p>
         SRC, including risk factors and management, is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7183.html" rel="external">
          "Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p>
         The management of SRC is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7183.html" rel="external">
          "Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2325307186">
         <span class="h3">
          Cardiac fibrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with SSc-like phenotype, myocardial fibrosis may be a predominant feature and therapeutic strategies would follow the management of SSc. (See
         <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">
          "Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults", section on 'Cardiac involvement'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2040626929">
         <span class="h2">
          Other features
         </span>
        </p>
        <p class="headingAnchor" id="H2093805587">
         <span class="h3">
          Arthritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Joint involvement occurs in approximately 60 percent of patients with MCTD. The arthritis resembles rheumatoid arthritis (RA), rather than the less severe arthritis associated with SLE. Like RA, it may be associated with boutonniere deformities and swan neck changes  (
         <a class="graphic graphic_picture graphicRef52452" href="/z/d/graphic/52452.html" rel="external">
          picture 16
         </a>
         ) [
         <a href="#rid34">
          34,39,103
         </a>
         ]. Other changes include small marginal erosions  (
         <a class="graphic graphic_diagnosticimage graphicRef60059" href="/z/d/graphic/60059.html" rel="external">
          image 3
         </a>
         ) [
         <a href="#rid119">
          119-121
         </a>
         ] and a destructive arthritis, including arthritis mutilans  (
         <a class="graphic graphic_diagnosticimage graphicRef66959" href="/z/d/graphic/66959.html" rel="external">
          image 4
         </a>
         and
         <a class="graphic graphic_picture graphicRef62581" href="/z/d/graphic/62581.html" rel="external">
          picture 17
         </a>
         ) [
         <a href="#rid34">
          34,122
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7502.html" rel="external">
          "Clinical manifestations of rheumatoid arthritis", section on 'Symptoms and physical findings'
         </a>
         .)
        </p>
        <p>
         Rheumatoid factor is found in approximately 70 percent of patients with MCTD [
         <a href="#rid35">
          35
         </a>
         ], and anticyclic citrullinated peptide (anti-CCP) antibodies are found in approximately 50 percent, especially in those MCTD patients who also fulfill the American College of Rheumatology diagnostic criteria for RA [
         <a href="#rid123">
          123
         </a>
         ].
        </p>
        <p>
         Management of inflammatory arthritis is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">
          "General principles and overview of management of rheumatoid arthritis in adults", section on 'Pharmacologic therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2661953371">
         <span class="h3">
          Musculoskeletal
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myalgias
         </strong>
         – Myalgia is a common symptom in patients with MCTD [
         <a href="#rid124">
          124
         </a>
         ]. In most patients, there is no demonstrable weakness, electromyographic (EMG) abnormalities, or elevation of muscle enzymes. It is often unclear whether the symptom represents a low-grade myositis, a physical deconditioning, or an associated fibromyalgia syndrome. (See
         <a class="medical medical_review" href="/z/d/html/2751.html" rel="external">
          "Approach to the patient with myalgia", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Management of myalgias is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2751.html" rel="external">
          "Approach to the patient with myalgia", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myositis
         </strong>
         – Patients with MCTD may develop an inflammatory myopathy and may have features of polymyositis (PM), dermatomyositis (DM), or immune-mediated necrotizing myopathy (IMNM). Myositis most commonly presents as an acute flare associated with proximal muscle weakness and creatinine kinase elevation but can also present as a low-grade, insidious, inflammatory myopathy [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The histology of muscle involvement in MCTD is the same as that of idiopathic inflammatory myopathy [
         <a href="#rid125">
          125,126
         </a>
         ], with features of both the vascular involvement of DM and the cell-mediated changes of PM [
         <a href="#rid127">
          127
         </a>
         ]. Some patients may also present with mechanic’s hands or extramuscular features of IMNM.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Management of inflammatory myopathy and the cutaneous manifestations of DM are discussed elsewhere:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5160.html" rel="external">
          "Initial treatment of dermatomyositis and polymyositis in adults", section on 'Initial therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13771.html" rel="external">
          "Cutaneous dermatomyositis in adults: Overview and initial management", section on 'Interventions for all patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4213503347">
         <span class="h3">
          Sicca
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prominent sicca symptoms (ie, keratoconjunctivitis sicca) are typically associated with Sjögren’s disease. However, 32 percent of the patients with MCTD also complain of sicca symptoms [
         <a href="#rid128">
          128
         </a>
         ].
        </p>
        <p>
         Sicca is characterized by dry eyes and dry mouth.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dry eyes
         </strong>
         – Dry eyes often lead to complaints irritation, grittiness, itching, or a foreign-body sensation in the eye, associated with reduced tear flow. (See
         <a class="medical medical_review" href="/z/d/html/5607.html" rel="external">
          "Clinical manifestations of Sjögren's disease: Exocrine gland disease", section on 'Dry eye'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dry mouth
         </strong>
         – Dry mouth is associated with oral dryness or difficulty swallowing dry foot without liquids. (See
         <a class="medical medical_review" href="/z/d/html/5607.html" rel="external">
          "Clinical manifestations of Sjögren's disease: Exocrine gland disease", section on 'Clinical features of dry mouth'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The management of sicca is discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14923.html" rel="external">
          "Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren’s disease", section on 'Treatment of dry mouth'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14923.html" rel="external">
          "Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren’s disease", section on 'Treatment of other sicca symptoms'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3702180620">
         <span class="h3">
          Gastrointestinal
         </span>
         <span class="headingEndMark">
          —
         </span>
         There have been case reports of hemoperitoneum, hematobilia, duodenal bleeding, megacolon, pancreatitis, ascites, protein-losing enteropathy, primary biliary cholangitis (previously referred to as primary biliary cirrhosis), portal hypertension, pneumatosis intestinalis, and autoimmune hepatitis [
         <a href="#rid43">
          43,129-131
         </a>
         ].
        </p>
        <p>
         Liver involvement in the form of chronic active hepatitis and Budd-Chiari syndrome has been described.
        </p>
        <p>
         Abdominal pain in MCTD may result from bowel hypomotility, serositis, mesenteric vasculitis, colonic perforation, and pancreatitis.
        </p>
        <p>
         The management of all of these issues is discussed in the separate topic reviews.
        </p>
        <p class="headingAnchor" id="H1163124265">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H3234101989">
         <span class="h2">
          When to suspect mixed connective tissue disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of mixed connective tissue disease (MCTD) should be suspected in a patient presenting with overlapping features of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), inflammatory myopathy, or rheumatoid arthritis (RA). However, overlapping features of SLE, SSc, inflammatory myopathy, and RA are seldom seen early in the disease. The overlapping features occur sequentially over several years [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p>
         Therefore, in early stages of the disease, most patients who develop MCTD cannot be easily differentiated from other well-defined systemic rheumatic diseases. Presenting symptoms are often nonspecific and include constitutional symptoms of fatigue and fever with a combination of arthralgia, myalgias, Raynaud phenomenon, and puffy digits. Rarely, MCTD may present with interstitial lung disease (ILD) or myositis. Feature that are atypical for MCTD are described below. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         Because the treatment of MCTD is driven by the individual manifestations, rather than the overall diagnosis, differentiating MCTD from other rheumatic diseases may not significantly affect patient outcomes.
        </p>
        <p class="headingAnchor" id="H4000673854">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial evaluation should include a thorough history, physical examination, and laboratory testing. Early referral to specialists, depending on organ involvement and severity of disease, is often appropriate, and multidisciplinary involvement (eg, by rheumatology, pulmonology) may be required.
        </p>
        <p class="headingAnchor" id="H3478550957">
         <span class="h3">
          History and physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         A comprehensive history and physical examination should be performed in all patients and should include nailfold capillary microscopy. (See
         <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">
          "Clinical manifestations and diagnosis of Raynaud phenomenon", section on 'Nailfold capillary microscopy'
         </a>
         .)
        </p>
        <p>
         The following history and physical examination findings are common in MCTD although are not specific to MCTD:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History
         </strong>
         – Patients should be questioned about the presence of any of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Constitutional symptoms, such as fever, fatigue, lymphadenopathy, or weight loss
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dysphagia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Painless oral or nasal ulcers
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Raynaud phenomenon or digital puffiness
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Joint pain or swelling
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chest pain suggestive of pericarditis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dyspnea or pleuritic chest pain suggestive of serositis or interstitial lung disease
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lower-extremity edema and hypertension
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Weakness when climbing stairs, getting out of a chair, or carrying heavy objects
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical examination
         </strong>
         – Pertinent physical examination findings include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Puffy or swollen fingers and/or nonpitting edema of the hands
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Skin thickening, either diffuse or limited to the hands, face, feet, and forearms
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Abnormal nailfold capillaroscopy with SSc pattern
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Skin lesions consistent with a malar rash or discoid lesions
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Polyarticular arthritis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Decreased or abnormal breath sounds that may indicate a pleural effusion, pneumonitis, or ILD
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Proximal muscle weakness
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H43646803">
         <span class="h3">
          Laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         We obtain the following routine laboratory tests to help exclude other processes and/or determine the extent of disease involvement:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complete blood count
         </strong>
         – Common abnormalities include leukopenia (mainly affecting lymphocytes), mild anemia, and/or thrombocytopenia [
         <a href="#rid43">
          43,133
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serum creatinine level and urinalysis with urine sediment
         </strong>
         – A serum creatinine and urinalysis with urine sediment may help identify the presence of kidney involvement and the degree of injury if present. Patients with evidence of abnormal kidney function, microscopic hematuria, proteinuria, or an active urinary sediment (eg, with dysmorphic red cells [acanthocytes] and/or red cell casts) may need further evaluation with a kidney biopsy.
        </p>
        <p>
        </p>
        <p>
         In addition to the routine laboratories described above, we perform the following autoantibody tests in all patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antinuclear antibody (ideally by human epidermoid carcinoma cell line indirect immunofluorescence testing)
         </strong>
         – Patients with MCTD typically have a positive antinuclear antibody (ANA) with a high titer coarse speckled pattern (commonly &gt;1:1000 and often &gt;1:10,000) [
         <a href="#rid134">
          134
         </a>
         ]. However, a speckled pattern may also be associated with autoantibodies to U1 ribonucleoprotein (RNP), Sm, Ro/SSA, and La/SSB.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Antibodies to double-stranded DNA (dsDNA), Sm, and Ro/SSA are occasionally seen transiently in patients with MCTD. If these autoantibodies remain detectable after repeat testing, the patient is more likely to develop another systemic rheumatic disease, such as SLE.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anti-U1 ribonucleoprotein antibodies
         </strong>
         – The presence of anti-U1 RNP antibodies remains a sine qua non for the diagnosis of MCTD. Nevertheless, anti-U1 RNP antibodies alone do not guarantee that a patient either has MCTD or will continue to display the MCTD phenotype.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         U1 RNP consists of ribonucleic acid (RNA) plus three proteins (A’, C, and a 68-70 kD protein). Additional information regarding antibody measurement and clinical utility is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1814.html" rel="external">
          "Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP", section on 'Anti-U1 RNP antibodies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Erythrocyte sedimentation rate and/or C-reactive protein levels
         </strong>
         – An elevation in erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) may be indicative of disease manifestations requiring immunosuppression.
        </p>
        <p>
        </p>
        <p>
         It is important to note that the presence of autoantibodies typically associated with RA does not preclude a diagnosis of MCTD. Rheumatoid factor in particular is common among patients with MCTD. In a series of 300 patients with MCTD, rheumatoid factor and anti-cyclic citrullinated peptide antibodies (ACPA) were reported in 28 percent and 7 percent, respectively [
         <a href="#rid135">
          135
         </a>
         ]. Hypergammaglobulinemia may also be present [
         <a href="#rid25">
          25,136
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H486679319">
         <span class="h2">
          Establishing the diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         We diagnose MCTD in patients who have:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anti-U1 RNP antibodies;
         <strong>
          and
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Have at least three of the following clinical features:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Digital swelling
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Raynaud phenomenon
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Synovitis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Myositis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acrosclerosis
        </p>
        <p>
        </p>
        <p>
         This approach is generally in accordance with accepted diagnostic criteria [
         <a href="#rid28">
          28-31
         </a>
         ].
        </p>
        <p>
         Challenges to diagnosing MCTD include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Heterogeneity of presentation
         </strong>
         – There is significant heterogeneity in disease presentations. MCTD may present with features of multiple rheumatic diseases, including SLE, SSc, inflammatory myopathy, and RA.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evolution to alternate diagnoses
         </strong>
         – While cases of MCTD have been reported to evolve into other systemic rheumatic diseases over time [
         <a href="#rid2">
          2,24,137
         </a>
         ], other reports indicate that true phenotypic conversion is rare [
         <a href="#rid138">
          138
         </a>
         ]. These differences may be due to the use of different classification criteria in these studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         One study followed the clinical course of 118 patients initially diagnosed with MCTD [
         <a href="#rid139">
          139
         </a>
         ]. Twelve percent developed another well-defined rheumatic condition over the course of 17 years; puffy hands predicted a stable MCTD phenotype.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other studies indicate that one in five patients initially diagnosed as having MCTD evolve into another rheumatic disease (eg, SSc, SLE, RA, Sjögren’s disease, and vasculitis) within five years of the MCTD diagnosis [
         <a href="#rid24">
          24,137,140
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Simultaneous diagnosis with lupus
         </strong>
         – Many clinically stable patients fulfill criteria for both SLE and MCTD. In one study of 20 MCTD patients, 47 percent also satisfied SLE criteria [
         <a href="#rid137">
          137
         </a>
         ]. In total, 37 out of 38 (97 percent) patients who satisfied MCTD criteria met Systemic Lupus International Collaborating Clinics (SLICC) SLE criteria, while 37 out of 79 (47 percent) RNP-positive patients who satisfied SLICC SLE criteria met MCTD criteria.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Published diagnostic criteria
         </strong>
         – While some argue that MCTD is a disease defined by presence of anti-U1 RNP, not all patients with anti-U1 RNP antibody have MCTD [
         <a href="#rid39">
          39,141,142
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Several attempts have been made to standardize the diagnostic criteria for MCTD [
         <a href="#rid28">
          28-30,143-145
         </a>
         ]. The Alarcón-Segovia and Kahn criteria have comparable sensitivity and specificity, and comparison of the four diagnostic criteria suggest that the Kasukawa criteria provides the highest sensitivity while both Alarcón-Segovia and Kahn criteria provide the maximum specificity [
         <a href="#rid6">
          6
         </a>
         ]. Thus, the Kasukawa criteria may be useful for screening patients while either the Alarcón-Segovia or Kahn criteria may be used to rule in the diagnosis of MCTD. However, this approach is not validated.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1934858072">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The distinction of mixed connective tissue disease (MCTD) from other systemic rheumatic diseases including overlap syndrome is a clinical challenge, particularly given the heterogeneity of disease presentations. In a single-center study, 61 percent of patients with MCTD was not correctly diagnosed at disease presentation [
         <a href="#rid138">
          138
         </a>
         ].
        </p>
        <p>
         An alternate diagnosis should be considered under the following circumstances:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Features atypical for MCTD
         </strong>
         – Multiple features are rarely found in association with MCTD, and their presence should prompt a thorough evaluation for systemic lupus erythematosus (SLE) (see
         <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">
          "Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Diagnosis'
         </a>
         ). These features include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Neurologic
         </strong>
         – Cerebritis, psychosis, or seizures
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pulmonary
         </strong>
         – Pleurisy, pulmonary hemorrhage
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hematologic
         </strong>
         – Pleural effusions, pleuritic pain, and alveolar hemorrhage, and thromboembolic disease
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Renal
         </strong>
         – Diffuse proliferative glomerulonephritis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additionally, the presence of cutaneous sclerosis or scleroderma renal crisis (SRC) should prompt a thorough evaluation for scleroderma, since these features are rarely associated with MCTD. (See
         <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">
          "Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Absence of U1 ribonucleoprotein antibodies
         </strong>
         – Patients with U1 ribonucleoprotein (RNP) antibodies cannot be diagnosed with MCTD. Patients who have some of the clinical features of MCTD but lack U1 RNP antibodies should be evaluated for alternative diagnoses:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Digital swelling, Raynaud phenomenon, and acrosclerosis should prompt an evaluation for scleroderma. (See
         <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">
          "Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Synovitis should prompt an evaluation for rheumatoid arthritis (RA) or another inflammatory arthritis. (See
         <a class="medical medical_review" href="/z/d/html/7504.html" rel="external">
          "Diagnosis and differential diagnosis of rheumatoid arthritis", section on 'Differential diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7504.html" rel="external">
          "Diagnosis and differential diagnosis of rheumatoid arthritis", section on 'Evaluation and diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Myositis should prompt an evaluation for an idiopathic myopathy. (See
         <a class="medical medical_review" href="/z/d/html/127066.html" rel="external">
          "Overview of and approach to the idiopathic inflammatory myopathies", section on 'Diagnostic approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Finally, it is important to remember that patients may meet criteria for MCTD and another rheumatic disease simultaneously. Therefore, a prior diagnosis of another rheumatic disease (eg, SLE) does not preclude an additional diagnosis of MCTD. (See
         <a class="medical medical_review" href="/z/d/html/1831.html" rel="external">
          "Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes", section on 'Early undifferentiated systemic rheumatic disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H370816187">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2366087860">
         <span class="h2">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of patients with mixed connective tissue disease (MCTD) requires continual reassessment for new or evolving disease manifestations. In general, the distinctive clinical characteristics of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and polymyositis (PM) appear sequentially over time. It is unusual for patients to exhibit overlapping features in the early stages of MCTD [
         <a href="#rid23">
          23,146-149
         </a>
         ]. Later in the disease course, patients may develop a true overlap syndrome, which simultaneously incorporates features of SLE, scleroderma, PM, rheumatoid arthritis (RA), and Sjogren’s disease.
        </p>
        <p>
         Since cardiopulmonary involvement can be a prominent characteristic of MCTD, we suggest obtaining a baseline transthoracic echocardiogram, high-resolution CT scan of the chest, and pulmonary function tests (including forced vital capacity and diffusing capacity for carbon monoxide) for all patients.
        </p>
        <p>
         In patients who have no evidence of cardiopulmonary disease at baseline, we recommend repeating an echocardiogram and pulmonary function tests on an annual basis to monitor for incident disease manifestations.
        </p>
        <p>
         Slow interstitial lung disease (ILD) progression may occur. Male gender and lack of arthritis are possible risk factors for ILD progression [
         <a href="#rid16">
          16
         </a>
         ]. High-titer anti-ribonucleoprotein (RNP) and/or anti-Ro52 antibodies have also been reported as risk factors for ILD progression; however, this antibody profile is more consistent with SLE rather than MCTD. Patients who have pulmonary arterial hypertension (PAH) or ILD should be monitored using the same algorithms developed for scleroderma. These issues are discussed in other topics. (See
         <a class="medical medical_review" href="/z/d/html/4377.html" rel="external">
          "Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Subsequent monitoring'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2437559322">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment is usually directed at the specific disease manifestations. Specific links are provided in the sections above. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
         The treatment of MCTD is largely extrapolated from treating similar symptoms in other rheumatic diseases [
         <a href="#rid150">
          150
         </a>
         ]. When first described, MCTD was treated predominantly with long-term glucocorticoids, but this strategy is inappropriate for most patients [
         <a href="#rid151">
          151-153
         </a>
         ].
        </p>
        <p>
         In general, features of MCTD that are also associated with SLE are managed with
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         in addition to other immunosuppressive agents, including glucocorticoids, which are selected based on the severity of the disease manifestations. (See
         <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">
          "Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Approach to drug therapy'
         </a>
         .)
        </p>
        <p>
         However, the SSc-like features of MCTD, with the exception of ILD, are not generally responsive to immunosuppressive therapies. (See
         <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">
          "Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults", section on 'General principles of management'
         </a>
         .)
        </p>
        <p>
         Glucocorticoids are typically contraindicated in patients with early, diffuse SSc because of their association with SRC. Because SRC has rarely been observed among patients with MCTD, glucocorticoids are not contraindicated for this patient population in the absence of other risk factors for SRC (eg, concomitant anti-U3 RNP or anti-RNA polymerase III antibodies).
        </p>
        <p class="headingAnchor" id="H136074487">
         <span class="h2">
          Considerations during pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no specific guidelines for patients with MCTD considering pregnancy. However, we suggest counselling similar to that used for patients with SLE. (See
         <a class="medical medical_review" href="/z/d/html/4679.html" rel="external">
          "Pregnancy in women with systemic lupus erythematosus", section on 'Pregnancy planning'
         </a>
         .)
        </p>
        <p>
         We also suggest screening patients contemplating pregnancy for ILD, PAH, and the antiphospholipid syndrome, since these diagnoses may raise additional management considerations [
         <a href="#rid154">
          154
         </a>
         ]. The evaluation of these diagnoses is discussed in other topics. (See
         <a class="medical medical_review" href="/z/d/html/4377.html" rel="external">
          "Overview of pulmonary complications of systemic sclerosis (scleroderma)", section on 'Evaluation for lung disease at time of SSc presentation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4678.html" rel="external">
          "Diagnosis of antiphospholipid syndrome", section on 'Antiphospholipid antibody testing'
         </a>
         .)
        </p>
        <p>
         The risk of medical and obstetric complications is similar to what has been reported for other systemic rheumatic diseases, and prepregnancy counseling to optimize disease control may improve outcomes [
         <a href="#rid154">
          154-157
         </a>
         ].
        </p>
        <p>
         Data from retrospective series indicate that use of immunosuppression including steroids was reported to be associated with better pregnancy outcomes. This is likely related to better disease activity control with immunosuppression [
         <a href="#rid154">
          154,157
         </a>
         ].
        </p>
        <p>
         Patients with severe Raynaud phenomenon in general often have low-birthweight infants [
         <a href="#rid158">
          158
         </a>
         ], presumably due to placental ischemia. This relationship has also been described in patients with MCTD [
         <a href="#rid159">
          159
         </a>
         ].
        </p>
        <p>
         The mechanism for other pregnancy complications is probably an autoimmune reaction against placental tissues, as immunostaining studies show deposits of fibrinogen, immunoglobulin G (IgG), IgM, IgA, and C3 localized to the trophoblast basement membrane [
         <a href="#rid160">
          160
         </a>
         ]. Furthermore, there is an association of antiendothelial antibodies with spontaneous abortion in MCTD [
         <a href="#rid161">
          161
         </a>
         ].
        </p>
        <p>
         Issues pertaining to the safety of immunosuppressive drugs during pregnancy and lactation are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">
          "Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Risk categories and treatment context'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1763177054">
         <span class="h1">
          PROGNOSIS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mortality
         </strong>
         – Estimates of the mortality associated with mixed connective tissue disease (MCTD) ranges from 16 to 28 percent at 10 to 12 years [
         <a href="#rid162">
          162-165
         </a>
         ]. The largest study of mortality in MCTD patients reported survival rates of 98, 96, and 88 percent at 5, 10 and 15 years after diagnosis among 280 patients [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         MCTD with anti-U1 ribonucleoprotein (RNP) positivity has better long-term survival than patients with systemic sclerosis (SSc) with positive anti-Scl70 and anti-RNA polymerase antibodies; this prognostic difference extends to those with pulmonary arterial hypertension (PAH) despite similar severity [
         <a href="#rid39">
          39,108
         </a>
         ]. Patients with MCTD also have a low prevalence of serious kidney disease and life-threatening neurologic manifestations [
         <a href="#rid10">
          10,133,166
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         PAH is the major cause of death in MCTD [
         <a href="#rid37">
          37,79,167
         </a>
         ]. Other risk factors for morality include:
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Interstitial lung disease (ILD) [
         <a href="#rid168">
          168
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anticardiolipin antibodies [
         <a href="#rid10">
          10
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Myocarditis [
         <a href="#rid48">
          48
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Renovascular hypertension [
         <a href="#rid169">
          169,170
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cerebral hemorrhage [
         <a href="#rid169">
          169,170
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Morbidity
         </strong>
         – Morbidity is quite high in patients with MCTD.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         As in patients with systemic lupus erythematosus (SLE), it is not uncommon for patients with MCTD to develop fibromyalgia. This can often become more debilitating than the primary disease [
         <a href="#rid151">
          151,152
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5624.html" rel="external">
          "Clinical manifestations and diagnosis of fibromyalgia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with severe Raynaud phenomena can rarely develop ischemic ulcers and even outright gangrene of the fingers. Such patients generally have a higher mortality [
         <a href="#rid164">
          164
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A small subset of patients with MCTD develops a deforming arthritis and even arthritis mutilans [
         <a href="#rid34">
          34,120,122
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Esophageal dysmotility can progress over time; as a result, some patients must undergo regular bougie dilatation. Gastroesophageal acid reflux may lead to Barrett's esophagus and, eventually, to carcinoma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical course
         </strong>
         – Long-term follow-up of patients with MCTD demonstrates that approximately one-third have a favorable outcome, one-third have a good outcome with treatment, and one-third have a more aggressive course. In a follow-up report of the original 25 patients, for example, nine (36 percent) required repeated courses of glucocorticoids [
         <a href="#rid162">
          162
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3157635383">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/134214.html" rel="external">
          "Society guideline links: Mixed connective tissue disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11410404">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Mixed connective tissue disease (MCTD) is defined as a systemic rheumatic disease characterized by the presence of high-titer anti-U1 ribonucleoprotein (U1 RNP) antibodies in combination with clinical features commonly seen in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), and polymyositis (PM). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – The annual incidence of MCTD is 0.2 to 1.9 per 100,000 and is more common among females than males. MCTD affects patients of all races and ages. (See
         <a class="local">
          'Epidemiology and pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – The early clinical features are nonspecific and may consist of puffy fingers, fatigue, arthralgias, myalgias, low-grade fever, and Raynaud phenomenon. Patients with MCTD may have multiple features of systemic lupus erythematosus (SLE) and scleroderma (SSc).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The SLE-like features include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cutaneous
         </strong>
         – Chilblains, discoid plaques, malar rash, panniculitis, and mucosal ulcerations are all associated with MCTD. (See
         <a class="local">
          'Cutaneous'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cardiac
         </strong>
         – Approximately 30 percent of MCTD patients have symptomatic heart disease, which may include pericarditis, myocarditis, accelerated atherosclerosis, and conduction abnormalities. (See
         <a class="local">
          'Cardiac'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Renal
         </strong>
         – Membranous nephropathy is the most common renal manifestation of MCTD; severe kidney disease is uncommon. (See
         <a class="local">
          'Renal'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Neurologic
         </strong>
         – Approximately 25 percent of patients with MCTD have a mild form of central nervous system (CNS) disease, most commonly trigeminal neuralgia or headache. Severe CNS disease is rare. (See
         <a class="local">
          'Neurologic'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most common SSc-like features include Raynaud phenomenon, gastrointestinal dysmotility (particularly of the upper gastrointestinal tract), interstitial lung disease (ILD), and pulmonary arterial hypertension (PAH). (See
         <a class="local">
          'Scleroderma-like features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients may also a destructive arthritis, myalgias, myositis, and sicca. (See
         <a class="local">
          'Other features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – The initial evaluation should include a thorough history, physical examination, and laboratory testing. Early referral to specialists, depending on organ involvement and severity of disease, is often appropriate, and multidisciplinary involvement may be required. (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We obtain a complete blood count, serum creatinine level and urinalysis with urine sediment, antinuclear antibody (ANA), and anti-U1 RNP autoantibodies. (See
         <a class="local">
          'Laboratory testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         We suggest obtaining a baseline echocardiogram, pulmonary function tests, and high-resolution CT scan in all patients due to the prevalence of cardiopulmonary manifestations, which are associated with significant morbidity and mortality. (See
         <a class="local">
          'Monitoring'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Establishing the diagnosis
         </strong>
         – We diagnose MCTD in patients with:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anti-U1 RNP antibodies;
         <strong>
          and
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         At least three of the following features:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Digital swelling
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Raynaud phenomenon
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Synovitis
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Myositis
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Acrosclerosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The diagnosis is complicated by the fact there is significant heterogeneity in terms of disease presentations. Additionally, some patients will evolve into other diagnoses, while other patients may simultaneously be diagnosed with another concomitant rheumatic disease (eg, SLE). (See
         <a class="local">
          'Establishing the diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The distinction of MCTD from other systemic rheumatic diseases including overlap syndrome is a clinical challenge, given the heterogeneity of presentations. Consideration must be given to the individual diseases that are required to present as overlapping as part of the diagnosis of MCTD, which include SLE, RA, inflammatory myopathy, SSc, and Raynaud phenomenon.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The absence of an anti-U1 RNP antibody or the presence of clinical features not typically associated with MCTD (eg, cerebritis, psychosis, seizure, diffuse proliferative glomerulonephritis) should prompt a search for alternate diagnoses. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Treatment of MCTD is directed at the specific disease manifestations. The approach for each is extrapolated from treating similar symptoms in SLE, SSc, and other rheumatic diseases:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">
          "Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults", section on 'General principles of management'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">
          "Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Management'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">
          "General principles and overview of management of rheumatoid arthritis in adults", section on 'Pharmacologic therapy'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5160.html" rel="external">
          "Initial treatment of dermatomyositis and polymyositis in adults", section on 'Initial therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – The 10-year mortality associated with MCTD ranges is approximately 20 percent. Risk factors for mortality include PAH, ILD, anticardiolipin antibodies, myocarditis, renovascular hypertension, and cerebral hemorrhage.
        </p>
        <p>
        </p>
        <p>
         Approximately one-third of patients have progressive disease. Patients with MCTD have high levels of morbidity due to concomitant pain syndromes, severe Raynaud phenomenon, deforming arthritis, esophageal dysmotility, and the complications of therapy with glucocorticoids. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2944562573">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Robert M Bennett, MD, FRCP, MACR, now deceased, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Gunnarsson R, Molberg O, Gilboe IM, et al. The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients. Ann Rheum Dis 2011; 70:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ungprasert P, Crowson CS, Chowdhary VR, et al. Epidemiology of Mixed Connective Tissue Disease, 1985-2014: A Population-Based Study. Arthritis Care Res (Hoboken) 2016; 68:1843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferucci ED, Johnston JM, Gordon C, et al. Prevalence of Mixed Connective Tissue Disease in a Population-Based Registry of American Indian/Alaska Native People in 2007. Arthritis Care Res (Hoboken) 2017; 69:1271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaipiainen-Seppänen O, Aho K. Incidence of rare systemic rheumatic and connective tissue diseases in Finland. J Intern Med 1996; 240:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elfving P, Marjoniemi O, Niinisalo H, et al. Estimating the incidence of connective tissue diseases and vasculitides in a defined population in Northern Savo area in 2010. Rheumatol Int 2016; 36:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           John KJ, Sadiq M, George T, et al. Clinical and Immunological Profile of Mixed Connective Tissue Disease and a Comparison of Four Diagnostic Criteria. Int J Rheumatol 2020; 2020:9692030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdelgalil Ali Ahmed S, Adam Essa ME, Ahmed AF, et al. Incidence and Clinical Pattern of Mixed Connective Tissue Disease in Sudanese Patients at Omdurman Military Hospital: Hospital-Based Study. Open Access Rheumatol 2021; 13:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guimarães F, Silvério-António M, Martinho J, et al. Clinical and immunological features of a Portuguese cohort of Mixed Connective Tissue Disease. Ann Rheum Dis 2022; 81:1454.
          </a>
         </li>
         <li class="breakAll">
          Nakae K, Furusawa F, Kasukawa R, et al. A nationwide epidemiological survey on diffuse collagen diseases: Estimation of prevalence rate in Japan. In: Mixed Connective Tissue Disease and Anti-nuclear Antibodies, Kasukawa R, Sharp G (Eds), Excerpta Medica, 1987. p.9.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burdt MA, Hoffman RW, Deutscher SL, et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999; 42:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lundberg I, Hedfors E. Clinical course of patients with anti-RNP antibodies. A prospective study of 32 patients. J Rheumatol 1991; 18:1511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christopher-Stine L, Wigley F. Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease. J Rheumatol 2003; 30:2725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008; 37:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuipers EJ, van Leeuwen MA, Nikkels PG, et al. Hemobilia due to vasculitis of the gall bladder in a patient with mixed connective tissue disease. J Rheumatol 1991; 18:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silver TM, Farber SJ, Bole GG, Martel W. Radiological features of mixed connective tissue disease and scleroderma--systemic lupus erythematosus overlap. Radiology 1976; 120:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khanna A, Suri JC, Ray A, Sharma RK. Silica associated mixed connective tissue disorder in a stone crusher. Indian J Occup Environ Med 2013; 17:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karsulovic C, Hojman LP, Seelmann DL, Wurmann PA. Diffuse Lymphadenopathy Syndrome as a Flare-Up Manifestation in Lupus and Mixed Connective Tissue Disease Following Mild COVID-19. Am J Case Rep 2021; 22:e932751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ali S, Almas T, Zaidi U, et al. A novel case of lupus nephritis and mixed connective tissue disorder in a COVID-19 patient. Ann Med Surg (Lond) 2022; 78:103653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flåm ST, Gunnarsson R, Garen T, et al. The HLA profiles of mixed connective tissue disease differ distinctly from the profiles of clinically related connective tissue diseases. Rheumatology (Oxford) 2015; 54:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carnero-Montoro E, Barturen G, Povedano E, et al. Epigenome-Wide Comparative Study Reveals Key Differences Between Mixed Connective Tissue Disease and Related Systemic Autoimmune Diseases. Front Immunol 2019; 10:1880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Somarelli JA, Mesa A, Rodriguez R, et al. Epitope mapping of the U1 small nuclear ribonucleoprotein particle in patients with systemic lupus erythematosus and mixed connective tissue disease. Lupus 2011; 20:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escolà-Vergé L, Pinal-Fernandez I, Fernandez-Codina A, et al. Mixed Connective Tissue Disease and Epitope Spreading: An Historical Cohort Study. J Clin Rheumatol 2017; 23:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cappelli S, Bellando Randone S, Martinović D, et al. "To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum 2012; 41:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennett RM, O'Connell DJ. Mixed connective tisssue disease: a clinicopathologic study of 20 cases. Semin Arthritis Rheum 1980; 10:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aringer M, Steiner G, Smolen JS. Does mixed connective tissue disease exist? Yes. Rheum Dis Clin North Am 2005; 31:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alves MR, Isenberg DA. "Mixed connective tissue disease": a condition in search of an identity. Clin Exp Med 2020; 20:159.
          </a>
         </li>
         <li class="breakAll">
          Kahn MF, Appelboom T. Syndrom de Sharp. In: Les maladies systemiques, 3rd ed, Kahn MF, Peltier AP, Meyer O, Piette JC (Eds), Flammarion, 1991. p.545.
         </li>
         <li class="breakAll">
          Alarcon Segovia D, Villareal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Mixed Connective Tissue Disease and Anti-nuclear Antibodies, Kasukawa R, Sharp G (Eds), Elsevier, 1987. p.33.
         </li>
         <li class="breakAll">
          Kasukawa R, Tojo T, Miyawaki S. Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Mixed Connective Tissue Disease and Antinuclear Antibodies, Kasukawa R, Sharp G (Eds), Elsevier, 1987. p.41.
         </li>
         <li class="breakAll">
          Sharp GC. Therapy and prognosis of MCTD. In: Mixed Connective Tissue Disease and Antinuclear Antibodies, Kasukawa R, Sharp G (Eds), Excerpta Medica, 1987. p.315.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lambova SN, Kuzmanova SI. Raynaud's phenomenon in common rheumatic diseases. Folia Med (Plovdiv) 2006; 48:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peller JS, Gabor GT, Porter JM, Bennett RM. Angiographic findings in mixed connective tissue disease. Correlation with fingernail capillary photomicroscopy and digital photoplethysmography findings. Arthritis Rheum 1985; 28:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennett RM, O'Connell DJ. The arthritis of mixed connective tissue disease. Ann Rheum Dis 1978; 37:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mimura Y, Ihn H, Jinnin M, et al. Rheumatoid factor isotypes in mixed connective tissue disease. Clin Rheumatol 2006; 25:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yin G, Cen XM, Yang M, Xie QB. [Detecting anti-cyclic citrullinated peptide antibody in patients with connective tissue diseases]. Sichuan Da Xue Xue Bao Yi Xue Ban 2011; 42:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lundberg IE. The prognosis of mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maddison PJ, Mogavero H, Reichlin M. Patterns of clinical disease associated with antibodies to nuclear ribonucleoprotein. J Rheumatol 1978; 5:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fairley JL, Hansen D, Proudman S, et al. Clinical Features of Systemic Sclerosis-Mixed Connective Tissue Disease and Systemic Sclerosis Overlap Syndromes. Arthritis Care Res (Hoboken) 2021; 73:732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farhey Y, Hess EV. Mixed connective tissue disease. Arthritis Care Res 1997; 10:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rasmussen EK, Ullman S, Høier-Madsen M, et al. Clinical implications of ribonucleoprotein antibody. Arch Dermatol 1987; 123:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sen S, Sinhamahapatra P, Choudhury S, et al. Cutaneous manifestations of mixed connective tissue disease: study from a tertiary care hospital in eastern India. Indian J Dermatol 2014; 59:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pope JE. Other manifestations of mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamza M. Orogenital ulcerations in mixed connective tissue disease. J Rheumatol 1985; 12:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willkens RF, Roth GJ, Novak A, Walike JW. Perforation of nasal septum in rheumatic diseases. Arthritis Rheum 1976; 19:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ungprasert P, Wannarong T, Panichsillapakit T, et al. Cardiac involvement in mixed connective tissue disease: a systematic review. Int J Cardiol 2014; 171:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hajas A, Szodoray P, Nakken B, et al. Clinical course, prognosis, and causes of death in mixed connective tissue disease. J Rheumatol 2013; 40:1134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lundberg IE. Cardiac involvement in autoimmune myositis and mixed connective tissue disease. Lupus 2005; 14:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haładyj E, Paradowska-Gorycka A, Felis-Giemza A, Olesińska M. Immunity and early atherosclerosis in the course of systemic lupus erythematosus, mixed connective tissue disease and antiphospholipid syndrome. Reumatologia 2016; 54:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kitridou RC, Akmal M, Turkel SB, et al. Renal involvement in mixed connective tissue disease: a longitudinal clinicopathologic study. Semin Arthritis Rheum 1986; 16:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennett RM, Spargo BH. Immune complex nephropathy in mixed connective tissue disease. Am J Med 1977; 63:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshida A, Morozumi K, Takeda A, Koyama K. [Nephropathy in patients with mixed connective tissue disease]. Ryumachi 1994; 34:976.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Celikbilek M, Elsurer R, Afsar B, et al. Mixed connective tissue disease: a case with scleroderma renal crisis following abortion. Clin Rheumatol 2007; 26:1545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheta J, Rijhwani S, Rust H. Scleroderma Renal Crisis in Mixed Connective Tissue Disease With Full Renal Recovery Within 3 Months: A Case Report With Expanding Treatment Modalities to Treat Each Clinical Sign as an Independent Entity. J Investig Med High Impact Case Rep 2017; 5:2324709617734012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madieh J, Khamayseh I, Hrizat A, et al. Scleroderma Renal Crisis in a Case of Mixed Connective Tissue Disease Treated Successfully with Angiotensin-Converting Enzyme Inhibitors. Case Rep Nephrol 2021; 2021:8862405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawai T, Murakami K, Kurasono Y. Morphometric analysis of the kidney lesions in mixed connective tissue disease (MCTD). Tohoku J Exp Med 1994; 174:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishioka R, Zoshima T, Hara S, et al. Urinary abnormality in mixed connective tissue disease predicts development of other connective tissue diseases and decrease in renal function. Mod Rheumatol 2022; 32:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennett RM, Bong DM, Spargo BH. Neuropsychiatric problems in mixed connective tissue disease. Am J Med 1978; 65:955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nowicka-Sauer K, Czuszynska Z, Majkowicz M, et al. Neuropsychological assessment in mixed connective tissue disease: comparison with systemic lupus erythematosus. Lupus 2012; 21:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hojaili B, Barland P. Trigeminal neuralgia as the first manifestation of mixed connective tissue disorder. J Clin Rheumatol 2006; 12:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagen NA, Stevens JC, Michet CJ Jr. Trigeminal sensory neuropathy associated with connective tissue diseases. Neurology 1990; 40:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bronshvag MM, Pyrstowsky SD, Traviesa DC. Vascular headaches in mixed connective tissue disease. Headache 1978; 18:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okada J, Hamana T, Kondo H. Anti-U1RNP antibody and aseptic meningitis in connective tissue diseases. Scand J Rheumatol 2003; 32:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmadi-Simab K, Lamprecht P, Reuter M, Gross WL. Pachymeningitis in mixed connective tissue disease. Ann Rheum Dis 2005; 64:1656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yasuda Y, Akiguchi I, Kameyama M. Sulindac-induced aseptic meningitis in mixed connective tissue disease. Clin Neurol Neurosurg 1989; 91:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman M, Gray RG. Ibuprofen-induced meningitis in mixed connective tissue disease. Clin Rheumatol 1982; 1:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karmacharya P, Mainali NR, Aryal MR, Lloyd B. Recurrent case of ibuprofen-induced aseptic meningitis in mixed connective tissue disease. BMJ Case Rep 2013; 2013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hajas A, Szodoray P, Barath S, et al. Sensorineural hearing loss in patients with mixed connective tissue disease: immunological markers and cytokine levels. J Rheumatol 2009; 36:1930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toyoda K, Tsuji H, Sadoshima S, et al. Brain hemorrhage in mixed connective tissue disease. A case report. Angiology 1994; 45:967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhinder S, Harbour K, Majithia V. Transverse myelitis, a rare neurological manifestation of mixed connective tissue disease--a case report and a review of literature. Clin Rheumatol 2007; 26:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kappes J, Bennett RM. Cauda equina syndrome in a patient with high titer anti-RNP antibodies. Arthritis Rheum 1982; 25:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mimura T, Usui T, Amano S, et al. Retinal vasculitis and vitreous hemorrhage associated with mixed connective tissue disease: retinal vasculitis in MCTD. Int Ophthalmol 2005; 26:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider F. [Progressive multifocal leukoencephalopathy as a cause of neurologic symptoms in Sharp syndrome]. Z Rheumatol 1991; 50:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsui H, Udaka F, Oda M, et al. Encephalopathy and severe neuropathy due to probable systemic vasculitis as an initial manifestation of mixed connective tissue disease. Neurol India 2006; 54:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luostarinen L, Himanen SL, Pirttilä T, Molnar G. Mixed connective tissue disease associated with chronic inflammatory demyelinating polyneuropathy. Scand J Rheumatol 1999; 28:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maramattom BV. Facial Myokymia Due to a Pontine Inflammatory Demyelinating Disorder Associated with Mixed Connective Tissue Disorder [MCTD]. Ann Indian Acad Neurol 2020; 23:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahmanzadeh R, Rahmanzade R, Zabihiyeganeh M. Posterior reversible encephalopathy syndrome in a patient with mixed connective tissue disease: a case report. J Med Case Rep 2016; 10:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan MU, Devlin JA, Fraser A. Adhesive arachnoiditis in mixed connective tissue disease: a rare neurological manifestation. BMJ Case Rep 2016; 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bull TM, Fagan KA, Badesch DB. Pulmonary vascular manifestations of mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grader-Beck T, Wigley FM. Raynaud's phenomenon in mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blockmans D, Vermylen J, Bobbaers H. Nailfold capillaroscopy in connective tissue disorders and in Raynaud's phenomenon. Acta Clin Belg 1993; 48:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furtado RN, Pucinelli ML, Cristo VV, et al. Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud's phenomenon in SLE patients. Lupus 2002; 11:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Todoroki Y, Kubo S, Nakano K, et al. Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD. Rheumatology (Oxford) 2022; 61:4875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lambova SN, Müller-Ladner U. The role of capillaroscopy in differentiation of primary and secondary Raynaud's phenomenon in rheumatic diseases: a review of the literature and two case reports. Rheumatol Int 2009; 29:1263.
          </a>
         </li>
         <li class="breakAll">
          Bennett RM. Mixed connective tissue disease and overlap syndromes. In: Textbook of Rheumatology, 7th, Harris ED, et al (Eds), WB Saunders, Philadelphia 2004. p.1241.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan WD, Hurst DJ, Harmon CE, et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore) 1984; 63:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fagundes MN, Caleiro MT, Navarro-Rodriguez T, et al. Esophageal involvement and interstitial lung disease in mixed connective tissue disease. Respir Med 2009; 103:854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nica AE, Alexa LM, Ionescu AO, et al. Esophageal disorders in mixed connective tissue diseases. J Med Life 2016; 9:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uzuki M, Kamataki A, Watanabe M, et al. Histological analysis of esophageal muscular layers from 27 autopsy cases with mixed connective tissue disease (MCTD). Pathol Res Pract 2011; 207:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMahan ZH, Kulkarni S, Chen J, et al. Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management. Nat Rev Rheumatol 2023; 19:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Végh J, Szilasi M, Soós G, et al. [Interstitial lung disease in mixed connective tissue disease]. Orv Hetil 2005; 146:2435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodolay E, Szekanecz Z, Dévényi K, et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford) 2005; 44:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunnarsson R, Aaløkken TM, Molberg Ø, et al. Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis 2012; 71:1966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeganathan N, Sathananthan M. Connective Tissue Disease-Related Interstitial Lung Disease: Prevalence, Patterns, Predictors, Prognosis, and Treatment. Lung 2020; 198:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung Diseases. N Engl J Med 2020; 383:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kozuka T, Johkoh T, Honda O, et al. Pulmonary involvement in mixed connective tissue disease: high-resolution CT findings in 41 patients. J Thorac Imaging 2001; 16:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devaraj A, Wells AU, Hansell DM. Computed tomographic imaging in connective tissue diseases. Semin Respir Crit Care Med 2007; 28:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Afeltra A, Zennaro D, Garzia P, et al. Prevalence of interstitial lung involvement in patients with connective tissue diseases assessed with high-resolution computed tomography. Scand J Rheumatol 2006; 35:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narula N, Narula T, Mira-Avendano I, et al. Interstitial lung disease in patients with mixed connective tissue disease: pilot study on predictors of lung involvement. Clin Exp Rheumatol 2018; 36:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boleto G, Reiseter S, Hoffmann-Vold AM, et al. POS0066 The phenotype of mixed connective tissue disease patients having associated interstitial lung disease. Ann Rheum Dis 2022; 81:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Celińska-Löwenhoff M, Pastuszczak M, Pełka K, et al. Associations between nailfold capillaroscopy findings and interstitial lung disease in patients with mixed connective tissue disease. Arch Med Sci 2020; 16:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szodoray P, Hajas A, Kardos L, et al. Distinct phenotypes in mixed connective tissue disease: subgroups and survival. Lupus 2012; 21:1412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venables PJ. Mixed connective tissue disease. Lupus 2006; 15:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naqvi S, Talib V, Aijaz R, et al. Autoamputation and Polyneuropathy in Mixed Connective Tissue Disorder: A Case Report. Cureus 2017; 9:e1313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alpert MA, Goldberg SH, Singsen BH, et al. Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation 1983; 68:1182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wigley FM, Lima JA, Mayes M, et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005; 52:2125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshida S. Pulmonary arterial hypertension in connective tissue diseases. Allergol Int 2011; 60:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobanski V, Giovannelli J, Lynch BM, et al. Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Arthritis Rheumatol 2016; 68:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodolay E, Csipo I, Gál I, et al. Anti-endothelial cell antibodies in mixed connective tissue disease: frequency and association with clinical symptoms. Clin Exp Rheumatol 2004; 22:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vegh J, Szodoray P, Kappelmayer J, et al. Clinical and immunoserological characteristics of mixed connective tissue disease associated with pulmonary arterial hypertension. Scand J Immunol 2006; 64:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasegawa EM, Caleiro MT, Fuller R, Carvalho JF. The frequency of anti-beta2-glycoprotein I antibodies is low and these antibodies are associated with pulmonary hypertension in mixed connective tissue disease. Lupus 2009; 18:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008; 58:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanchez O, Sitbon O, Jaïs X, et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006; 130:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yasuoka H, Shirai Y, Tamura Y, et al. Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Circ J 2018; 82:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K, et al. Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ J 2011; 75:2668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ding Y, Qian J, Zhang S, et al. Immunosuppressive therapy in patients with connective tissue disease-associated pulmonary arterial hypertension: A systematic review. Int J Rheum Dis 2022; 25:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashraf M, Gopikrishnan K, Umamahesvaran B, Sambandam SN. Presentation of calcinosis cutis universalis in mixed connective tissue disorder: an encounter during hip arthroplasty. BMJ Case Rep 2017; 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamura K, Takahara M, Masunaga K, et al. Subcutaneous calcification of the lower legs in a patient with mixed connective tissue disease. J Dermatol 2011; 38:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Connell DJ, Bennett RM. Mixed connective tissue disease--clinical and radiological aspects of 20 cases. Br J Radiol 1977; 50:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Niembro F, Alarcón-Segovia D, Hernández-Ortíz J. Articular manifestations of mixed connective tissue disease. Arthritis Rheum 1979; 22:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-Cordero E, López-Zepeda J. Resorptive arthropathy and rib erosions in mixed connective tissue disease. J Rheumatol 1990; 17:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halla JT, Hardin JG. Clinical features of the arthritis of mixed connective tissue disease. Arthritis Rheum 1978; 21:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takasaki Y, Yamanaka K, Takasaki C, et al. Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. Mod Rheumatol 2004; 14:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall S, Hanrahan P. Muscle involvement in mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oxenhandler R, Hart M, Corman L, et al. Pathology of skeletal muscle in mixed connective tissue disease. Arthritis Rheum 1977; 20:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg SA, Amato AA. Inflammatory myopathy associated with mixed connective tissue disease and scleroderma renal crisis. Muscle Nerve 2001; 24:1562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vianna MA, Borges CT, Borba EF, et al. Myositis in mixed connective tissue disease: a unique syndrome characterized by immunohistopathologic elements of both polymyositis and dermatomyositis. Arq Neuropsiquiatr 2004; 62:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Usuba FS, Lopes JB, Fuller R, et al. Sjögren's syndrome: An underdiagnosed condition in mixed connective tissue disease. Clinics (Sao Paulo) 2014; 69:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall JB, Kretschmar JM, Gerhardt DC, et al. Gastrointestinal manifestations of mixed connective tissue disease. Gastroenterology 1990; 98:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aoki S, Tada Y, Ohta A, et al. [Autoimmune hepatitis associated with mixed connective tissue disease: report of a case and a review of the literature]. Nihon Rinsho Meneki Gakkai Kaishi 2001; 24:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishida S, Fujimoto T, Usui T, et al. [Mixed connective tissue disease (MCTD) with severe acute pancreatitis]. Nihon Naika Gakkai Zasshi 2001; 90:1518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortega-Hernandez OD, Shoenfeld Y. Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment. Best Pract Res Clin Rheumatol 2012; 26:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharp GC, Irvin WS, May CM, et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. N Engl J Med 1976; 295:1149.
          </a>
         </li>
         <li class="breakAll">
          Bennett RM. Mixed connective tissue disease and other overlap syndromes. In: Textbook of Rheumatology, 7th ed, Kelley W, Harris EDJ, Ruddy SH, Sledge G (Eds), WB Saunders, 2004. p.1241.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boleto G, Reiseter S, Hoffmann-Vold AM, et al. The phenotype of mixed connective tissue disease patients having associated interstitial lung disease. Semin Arthritis Rheum 2023; 63:152258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hämeenkorpi R, Ruuska P, Forsberg S, et al. More evidence of distinctive features of mixed connective tissue disease. Scand J Rheumatol 1993; 22:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiseter S, Gunnarsson R, Corander J, et al. Disease evolution in mixed connective tissue disease: results from a long-term nationwide prospective cohort study. Arthritis Res Ther 2017; 19:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wanzenried A, Garaiman A, Jordan S, et al. Challenges in the management of mixed connective tissue disease: a retrospective analysis of the MCTD cohort in a  tertiary referral centre. Ann Rheum Dis 2021; 80:1233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Hoogen FH, Spronk PE, Boerbooms AM, et al. Long-term follow-up of 46 patients with anti-(U1)snRNP antibodies. Br J Rheumatol 1994; 33:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi YH, Li R, Chen S, et al. [Analysis of clinical features and the outcome in 91 cases of mixed connective tissue diseases]. Beijing Da Xue Xue Bao 2012; 44:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jury EC, D'Cruz D, Morrow WJ. Autoantibodies and overlap syndromes in autoimmune rheumatic disease. J Clin Pathol 2001; 54:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nihtyanova SI, Sari A, Harvey JC, et al. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis. Arthritis Rheumatol 2020; 72:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jonsson J, Norberg R. Symptomatology and diagnosis in connective tissue disease. II. Evaluations and follow-up examinations in consequence of a speckled antinuclear immunofluorescence pattern. Scand J Rheumatol 1978; 7:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doria A, Ghirardello A, de Zambiasi P, et al. Japanese diagnostic criteria for mixed connective tissue disease in Caucasian patients. J Rheumatol 1992; 19:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka Y, Kuwana M, Fujii T, et al. 2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. Mod Rheumatol 2021; 31:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman RW, Maldonado ME. Immune pathogenesis of Mixed Connective Tissue Disease: a short analytical review. Clin Immunol 2008; 128:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piirainen HI, Kurki PT. Clinical and serological follow-up of patients with polyarthritis, Raynaud's phenomenon, and circulating RNP antibodies. Scand J Rheumatol 1990; 19:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piirainen HI. Patients with arthritis and anti-U1-RNP antibodies: a 10-year follow-up. Br J Rheumatol 1990; 29:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharp GC, Anderson PC. Current concepts in the classification of connective tissue diseases. Overlap syndromes and mixed connective tissue disease (MCTD). J Am Acad Dermatol 1980; 2:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaigne B, Scirè CA, Talarico R, et al. Mixed connective tissue disease: state of the art on clinical practice guidelines. RMD Open 2018; 4:e000783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morand EF, Miller MH, Whittingham S, Littlejohn GO. Fibromyalgia syndrome and disease activity in systemic lupus erythematosus. Lupus 1994; 3:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Middleton GD, McFarlin JE, Lipsky PE. The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. Arthritis Rheum 1994; 37:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manohar H, Kuppili PP, Menon V. Major depression: An under reported neuropsychiatric manifestation of Mixed Connective Tissue Disease. Asian J Psychiatr 2017; 30:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radin M, Schreiber K, Cuadrado MJ, et al. Pregnancy outcomes in mixed connective tissue disease: a multicentre study. Rheumatology (Oxford) 2019; 58:2000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kitridou RC. Pregnancy in mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung L, Flyckt RL, Colón I, et al. Outcome of pregnancies complicated by systemic sclerosis and mixed connective tissue disease. Lupus 2006; 15:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tardif ML, Mahone M. Mixed connective tissue disease in pregnancy: A case series and systematic literature review. Obstet Med 2019; 12:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahl LE, Blair C, Ramsey-Goldman R, Steen VD. Pregnancy outcomes in women with primary Raynaud's phenomenon. Arthritis Rheum 1990; 33:1249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lundberg I, Hedfors E. Pregnancy outcome in patients with high titer anti-RNP antibodies. A retrospective study of 40 pregnancies. J Rheumatol 1991; 18:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ackerman J, Gonzalez EF, Gilbert-Barness E. Immunological studies of the placenta in maternal connective tissue disease. Pediatr Dev Pathol 1999; 2:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodolay E, Bojan F, Szegedi G, et al. Cytotoxic endothelial cell antibodies in mixed connective tissue disease. Immunol Lett 1989; 20:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nimelstein SH, Brody S, McShane D, Holman HR. Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine (Baltimore) 1980; 59:239.
          </a>
         </li>
         <li class="breakAll">
          Miyawaki S, Onodera H. Clinical course and prognosis of patients with mixed connective tissue disease. In: Mixed Connective Tissue Disease and Antinuclear Antibodies, Kasukawa R, Sharp G (Eds), Excerpta Medica, 1987. p.331.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gendi NS, Welsh KI, Van Venrooij WJ, et al. HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic followup of 46 patients. Arthritis Rheum 1995; 38:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunnarsson R, Hetlevik SO, Lilleby V, Molberg Ø. Mixed connective tissue disease. Best Pract Res Clin Rheumatol 2016; 30:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aringer M, Smolen JS. Mixed connective tissue disease: what is behind the curtain? Best Pract Res Clin Rheumatol 2007; 21:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassoun PM. Pulmonary arterial hypertension complicating connective tissue diseases. Semin Respir Crit Care Med 2009; 30:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiseter S, Gunnarsson R, Mogens Aaløkken T, et al. Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study. Rheumatology (Oxford) 2018; 57:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuwana M, Kaburaki J, Okano Y, et al. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agapoff Iv JR. A Rare Case of Fatal Hemorrhagic Stroke in a Young Female with Early Mixed Connective Tissue Disease. Case Rep Rheumatol 2021; 2021:5321438.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7546 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21398332" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26946215" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Epidemiology of Mixed Connective Tissue Disease, 1985-2014: A Population-Based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27788293" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Prevalence of Mixed Connective Tissue Disease in a Population-Based Registry of American Indian/Alaska Native People in 2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8810933" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Incidence of rare systemic rheumatic and connective tissue diseases in Finland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27053177" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Estimating the incidence of connective tissue diseases and vasculitides in a defined population in Northern Savo area in 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32411251" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical and Immunological Profile of Mixed Connective Tissue Disease and a Comparison of Four Diagnostic Criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34916856" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Incidence and Clinical Pattern of Mixed Connective Tissue Disease in Sudanese Patients at Omdurman Military Hospital: Hospital-Based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinical and immunological features of a Portuguese cohort of Mixed Connective Tissue Disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinical and immunological features of a Portuguese cohort of Mixed Connective Tissue Disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10323445" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1765975" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Clinical course of patients with anti-RNP antibodies. A prospective study of 32 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14719225" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17977585" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Drug-induced lupus due to anti-tumor necrosis factor alpha agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2066956" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hemobilia due to vasculitis of the gall bladder in a patient with mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/935473" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Radiological features of mixed connective tissue disease and scleroderma--systemic lupus erythematosus overlap.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24421595" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Silica associated mixed connective tissue disorder in a stone crusher.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34504052" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Diffuse Lymphadenopathy Syndrome as a Flare-Up Manifestation in Lupus and Mixed Connective Tissue Disease Following Mild COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35495962" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A novel case of lupus nephritis and mixed connective tissue disorder in a COVID-19 patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25187641" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The HLA profiles of mixed connective tissue disease differ distinctly from the profiles of clinically related connective tissue diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31440254" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Epigenome-Wide Comparative Study Reveals Key Differences Between Mixed Connective Tissue Disease and Related Systemic Autoimmune Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21362751" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Epitope mapping of the U1 small nuclear ribonucleoprotein particle in patients with systemic lupus erythematosus and mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28248800" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Mixed Connective Tissue Disease and Epitope Spreading: An Historical Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4621694" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21959290" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : "To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7414333" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Mixed connective tisssue disease: a clinicopathologic study of 20 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16084315" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Does mixed connective tissue disease exist? Yes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32130548" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : "Mixed connective tissue disease": a condition in search of an identity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32130548" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : "Mixed connective tissue disease": a condition in search of an identity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32130548" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : "Mixed connective tissue disease": a condition in search of an identity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32130548" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : "Mixed connective tissue disease": a condition in search of an identity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32130548" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : "Mixed connective tissue disease": a condition in search of an identity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17668693" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Raynaud's phenomenon in common rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3874627" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Angiographic findings in mixed connective tissue disease. Correlation with fingernail capillary photomicroscopy and digital photoplethysmography findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/718271" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The arthritis of mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16391886" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Rheumatoid factor isotypes in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21827002" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : [Detecting anti-cyclic citrullinated peptide antibody in patients with connective tissue diseases].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16084324" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The prognosis of mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/310884" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Patterns of clinical disease associated with antibodies to nuclear ribonucleoprotein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32058672" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Clinical Features of Systemic Sclerosis-Mixed Connective Tissue Disease and Systemic Sclerosis Overlap Syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9362600" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3495241" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Clinical implications of ribonucleoprotein antibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24470658" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Cutaneous manifestations of mixed connective tissue disease: study from a tertiary care hospital in eastern India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16084323" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Other manifestations of mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4045874" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Orogenital ulcerations in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1252263" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Perforation of nasal septum in rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24433611" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Cardiac involvement in mixed connective tissue disease: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23637328" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Clinical course, prognosis, and causes of death in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16218472" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Cardiac involvement in autoimmune myositis and mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27826173" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Immunity and early atherosclerosis in the course of systemic lupus erythematosus, mixed connective tissue disease and antiphospholipid syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3563525" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Renal involvement in mixed connective tissue disease: a longitudinal clinicopathologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/143887" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Immune complex nephropathy in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7863388" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : [Nephropathy in patients with mixed connective tissue disease].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17119864" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Mixed connective tissue disease: a case with scleroderma renal crisis following abortion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29051891" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Scleroderma Renal Crisis in Mixed Connective Tissue Disease With Full Renal Recovery Within 3 Months: A Case Report With Expanding Treatment Modalities to Treat Each Clinical Sign as an Independent Entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33505743" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Scleroderma Renal Crisis in a Case of Mixed Connective Tissue Disease Treated Successfully with Angiotensin-Converting Enzyme Inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7900153" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Morphometric analysis of the kidney lesions in mixed connective tissue disease (MCTD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33706652" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Urinary abnormality in mixed connective tissue disease predicts development of other connective tissue diseases and decrease in renal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/217265" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Neuropsychiatric problems in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22433916" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Neuropsychological assessment in mixed connective tissue disease: comparison with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16755246" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Trigeminal neuralgia as the first manifestation of mixed connective tissue disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2161090" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Trigeminal sensory neuropathy associated with connective tissue diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/669945" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Vascular headaches in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14626633" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Anti-U1RNP antibody and aseptic meningitis in connective tissue diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16227419" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Pachymeningitis in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2548792" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Sulindac-induced aseptic meningitis in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6985377" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Ibuprofen-induced meningitis in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23632618" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Recurrent case of ibuprofen-induced aseptic meningitis in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19684145" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Sensorineural hearing loss in patients with mixed connective tissue disease: immunological markers and cytokine levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7978512" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Brain hemorrhage in mixed connective tissue disease. A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16391892" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Transverse myelitis, a rare neurological manifestation of mixed connective tissue disease--a case report and a review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6279119" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Cauda equina syndrome in a patient with high titer anti-RNP antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17200794" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Retinal vasculitis and vitreous hemorrhage associated with mixed connective tissue disease: retinal vasculitis in MCTD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1746173" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : [Progressive multifocal leukoencephalopathy as a cause of neurologic symptoms in Sharp syndrome].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16679652" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Encephalopathy and severe neuropathy due to probable systemic vasculitis as an initial manifestation of mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10568432" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Mixed connective tissue disease associated with chronic inflammatory demyelinating polyneuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32606527" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Facial Myokymia Due to a Pontine Inflammatory Demyelinating Disorder Associated with Mixed Connective Tissue Disorder [MCTD].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27250498" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Posterior reversible encephalopathy syndrome in a patient with mixed connective tissue disease: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27986694" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Adhesive arachnoiditis in mixed connective tissue disease: a rare neurological manifestation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16084318" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Pulmonary vascular manifestations of mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16084319" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Raynaud's phenomenon in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8388601" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Nailfold capillaroscopy in connective tissue disorders and in Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11899953" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud's phenomenon in SLE patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35285493" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19547979" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : The role of capillaroscopy in differentiation of primary and secondary Raynaud's phenomenon in rheumatic diseases: a review of the literature and two case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19547979" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : The role of capillaroscopy in differentiation of primary and secondary Raynaud's phenomenon in rheumatic diseases: a review of the literature and two case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6700436" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19201182" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Esophageal involvement and interstitial lung disease in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27453743" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Esophageal disorders in mixed connective tissue diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21620578" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Histological analysis of esophageal muscular layers from 27 autopsy cases with mixed connective tissue disease (MCTD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36747090" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16408383" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : [Interstitial lung disease in mixed connective tissue disease].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15716315" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22550317" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32780179" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Connective Tissue Disease-Related Interstitial Lung Disease: Prevalence, Patterns, Predictors, Prognosis, and Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32877584" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Spectrum of Fibrotic Lung Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11292211" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Pulmonary involvement in mixed connective tissue disease: high-resolution CT findings in 41 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17764057" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Computed tomographic imaging in connective tissue diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17062440" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Prevalence of interstitial lung involvement in patients with connective tissue diseases assessed with high-resolution computed tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29745875" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Interstitial lung disease in patients with mixed connective tissue disease: pilot study on predictors of lung involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : POS0066 The phenotype of mixed connective tissue disease patients having associated interstitial lung disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32190139" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Associations between nailfold capillaroscopy findings and interstitial lung disease in patients with mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22864236" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Distinct phenotypes in mixed connective tissue disease: subgroups and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16634365" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28690947" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Autoamputation and Polyneuropathy in Mixed Connective Tissue Disorder: A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6640871" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Cardiovascular manifestations of mixed connective tissue disease in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15986394" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22015567" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Pulmonary arterial hypertension in connective tissue diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26415038" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15301236" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Anti-endothelial cell antibodies in mixed connective tissue disease: frequency and association with clinical symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16784493" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Clinical and immunoserological characteristics of mixed connective tissue disease associated with pulmonary arterial hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19433462" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : The frequency of anti-beta2-glycoprotein I antibodies is low and these antibodies are associated with pulmonary hypertension in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18240255" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16840400" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28904255" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21873802" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35699128" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Immunosuppressive therapy in patients with connective tissue disease-associated pulmonary arterial hypertension: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28289001" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Presentation of calcinosis cutis universalis in mixed connective tissue disorder: an encounter during hip arthroplasty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21434985" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Subcutaneous calcification of the lower legs in a patient with mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/901973" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Mixed connective tissue disease--clinical and radiological aspects of 20 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/758918" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Articular manifestations of mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2359089" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Resorptive arthropathy and rib erosions in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/666870" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Clinical features of the arthritis of mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17143695" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16084322" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Muscle involvement in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/324486" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Pathology of skeletal muscle in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11745962" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Inflammatory myopathy associated with mixed connective tissue disease and scleroderma renal crisis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15608947" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Myositis in mixed connective tissue disease: a unique syndrome characterized by immunohistopathologic elements of both polymyositis and dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24626939" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Sjögren's syndrome: An underdiagnosed condition in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2323516" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Gastrointestinal manifestations of mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11411090" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : [Autoimmune hepatitis associated with mixed connective tissue disease: report of a case and a review of the literature].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11573273" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : [Mixed connective tissue disease (MCTD) with severe acute pancreatitis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22424193" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1086429" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1086429" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37696231" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : The phenotype of mixed connective tissue disease patients having associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8480140" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : More evidence of distinctive features of mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29268795" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Disease evolution in mixed connective tissue disease: results from a long-term nationwide prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Challenges in the management of mixed connective tissue disease: a retrospective analysis of the MCTD cohort in a  tertiary referral centre
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8000737" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Long-term follow-up of 46 patients with anti-(U1)snRNP antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22517002" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : [Analysis of clinical features and the outcome in 91 cases of mixed connective tissue diseases].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11328831" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Autoantibodies and overlap syndromes in autoimmune rheumatic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31682743" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/366740" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Symptomatology and diagnosis in connective tissue disease. II. Evaluations and follow-up examinations in consequence of a speckled antinuclear immunofluorescence pattern.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1629824" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Japanese diagnostic criteria for mixed connective tissue disease in Caucasian patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31903831" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : 2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18439877" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Immune pathogenesis of Mixed Connective Tissue Disease: a short analytical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2408141" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Clinical and serological follow-up of patients with polyarthritis, Raynaud's phenomenon, and circulating RNP antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2224402" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Patients with arthritis and anti-U1-RNP antibodies: a 10-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6988473" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Current concepts in the classification of connective tissue diseases. Overlap syndromes and mixed connective tissue disease (MCTD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30402271" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Mixed connective tissue disease: state of the art on clinical practice guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7951304" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Fibromyalgia syndrome and disease activity in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8053957" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28753451" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Major depression: An under reported neuropsychiatric manifestation of Mixed Connective Tissue Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31079145" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Pregnancy outcomes in mixed connective tissue disease: a multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16084321" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Pregnancy in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17080915" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Outcome of pregnancies complicated by systemic sclerosis and mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30891090" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Mixed connective tissue disease in pregnancy: A case series and systematic literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2390127" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Pregnancy outcomes in women with primary Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1713270" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Pregnancy outcome in patients with high titer anti-RNP antibodies. A retrospective study of 40 pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9841702" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Immunological studies of the placenta in maternal connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2714845" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Cytotoxic endothelial cell antibodies in mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6967141" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Mixed connective tissue disease: a subsequent evaluation of the original 25 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6967141" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Mixed connective tissue disease: a subsequent evaluation of the original 25 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7848317" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic followup of 46 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27421219" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18068860" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Mixed connective tissue disease: what is behind the curtain?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19634082" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Pulmonary arterial hypertension complicating connective tissue diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28379478" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8129766" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34745681" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : A Rare Case of Fatal Hemorrhagic Stroke in a Young Female with Early Mixed Connective Tissue Disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
